Last updated: February 19, 2026
Prevacid (lansoprazole) is a proton pump inhibitor used to treat gastric acid-related conditions. The drug is marketed globally, with manufacturing and distribution primarily handled by major pharmaceutical companies.
Key Suppliers and Manufacturers
1. Takeda Pharmaceutical Company
Takeda developed Prevacid and owns the brand. It is the leading supplier, manufacturing, and marketing the drug in several regions, including the United States and Europe.
- Manufacturing Facilities: Takeda operates manufacturing plants in Japan, the United States, and other countries.
- Market Presence: Prevacid is marketed directly by Takeda in North America, Europe, and select other regions.
- Formulations: Capsules (delayed-release and oral disintegrating tablets), suspensions.
2. Contract Manufacturers
Several third-party contract manufacturing organizations produce generic versions of lansoprazole under licensing or as generics, often supplying to global markets.
- Fujifilm Toyama Chemical Co. (Japan) — original manufacturer of lansoprazole prior to Takeda's development.
- Teva Pharmaceutical Industries — produces generic lansoprazole available in multiple markets.
- Sandoz (Novartis) — manufactures generic lansoprazole.
- Mylan (now part of Viatris) — offers generic lansoprazole formulations.
3. Generic Suppliers
In regions where patent exclusivity has expired, generic manufacturers supply Lansoprazole:
| Supplier |
Region |
Formulations |
Market Share (Est.) |
| Teva |
Global |
Capsules, tablets |
Approximately 20-30% in North America |
| Mylan |
Global |
Capsules |
Significant in Europe and Asia |
| Sandoz |
Europe, Asia |
Capsules |
Growing market share |
| Sun Pharmaceutical |
India, Asia |
Capsules, suspensions |
Leading generics in India |
4. Active Pharmaceutical Ingredient (API) Suppliers
Lansoprazole API is sourced from multiple vendors, including:
- Global API Manufacturers: Jiangsu Hengrui Medicine, Zhejiang Guoguang Pharmaceutical Co., Ltd.
- Regional Suppliers: Fine chemicals and intermediates produced in India, China, and South Korea.
5. Distribution and Supply Chain
Distribution centers are operated by both brand owners and generic manufacturers. Supply chains include wholesalers, distributors, and pharmacy chains to ensure global availability.
Regulatory and Patent Landscape
- The original patent for Prevacid expired in most markets by 2015, facilitating rapid proliferation of generics.
- Takeda retains patent rights for formulations and delivery mechanisms in some regions until 2023-2025 ([1]).
Summary of Major Market Sources
| Company |
Role |
Primary Regions |
Product Focus |
Notes |
| Takeda |
Brand manufacturer |
US, Europe, Japan |
Branded lansoprazole |
Patent holder, innovator |
| Teva |
Generic producer |
North America, Europe |
Generic capsules |
Broad portfolio |
| Mylan |
Generic manufacturer |
International |
Generic formulations |
Global supply |
| Sun Pharma |
API and formulations |
India, Asia |
Generics, API |
Largest Indian producer |
Key Takeaways
- Takeda is the sole supplier of the branded Prevacid.
- Several generic manufacturers, including Teva, Mylan, and Sandoz, supply generic lansoprazole.
- API sourcing primarily occurs in China, India, and Korea.
- Patent expiration in many regions has increased the number of suppliers.
- Distribution networks ensure global availability, with some markets dominated by branded products and others by generics.
FAQs
Q1: Who manufactures the original Prevacid?
Takeda developed and markets the original Prevacid and owns the intellectual property rights.
Q2: Are there multiple suppliers for generic lansoprazole?
Yes. Teva, Mylan, Sandoz, and Sun Pharma are leading generic suppliers.
Q3: When did patent expiry allow generics to enter the market?
Most patents expired between 2014 and 2016, enabling generics to proliferate worldwide.
Q4: Where is the API for lansoprazole produced?
Major API production occurs in China, India, and South Korea.
Q5: How does market share differ globally?
Branded Prevacid dominates in regions with patent protections, while generics hold larger shares where patents have expired.
References
- U.S. Food and Drug Administration. (2022). Patent Expiry and Market Exclusivity Data for Lansoprazole.
- IMS Health. (2021). Global Generic Drugs Market Report.
- Takeda Pharmaceutical Company. (2022). Annual Report.
- European Medicines Agency. (2022). Marketing Authorizations for Lansoprazole.
- Indian Pharmaceutical Directory. (2022). API Manufacturers.
